Retrospective Study of Myocardial Damage in COVID-19
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Wuhan Union Hospital, China
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- The myocardial injury incidence
- Last Updated
- 6 years ago
Overview
Brief Summary
This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients. There is no additional examination and treatment for this project.
Detailed Description
The epidemic of the COVID-19 has expanded from Wuhan through out China, and is being exported to a growing number of countries. Recently, investigators have revealed that acute myocardial injury is existed in 7.2% patients with COVID-19, and this proportion in patients admitted to the ICU (22.2%) is higher than patients not treated in the ICU (2.0%). Thus, cardiac troponin I (cTNI), the biomarker of cardiac injury, might be a clinical predictor of COVID-19 patient outcomes. This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients.
Investigators
Xiang Cheng
Professor
Wuhan Union Hospital, China
Eligibility Criteria
Inclusion Criteria
- •(1) Age ≥18 years. (2) Laboratory (RT-PCR) confirmed infection with SARS-CoV-
- •(3) Lung involvement confirmed with chest imaging.
Exclusion Criteria
- •No cTnI test on admission
Outcomes
Primary Outcomes
The myocardial injury incidence
Time Frame: 75 days
The myocardial injury incidence of COVID-19 patients
The risk factors analysis for the death
Time Frame: 75 days
The risk factors analysis for the death of COVID-19 patients
Secondary Outcomes
- Clinical course(75 days)
- Cardiovascular comorbidity(75 days)
- Clinical characteristics(75 days)
- Analysis of causes of death(75 days)